Asthma and lower airway diseaseExhaled nitric oxide and blood eosinophilia: Independent markers of preventable risk
References (19)
Complex airway disease: an approach to assessment and management
Lancet Respir Med
(2013)- et al.
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial
Lancet
(2002) - et al.
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Lancet
(2012) - et al.
Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial
Lancet
(2011) - et al.
Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations
Eur Respir J
(2006) - et al.
Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial
Eur Respir J
(2007) - et al.
Lebrikizumab treatment in adults with asthma
N Engl J Med
(2011) - et al.
Dupilumab in Persistent asthma with elevated eosinophil levels
N Engl J Med
(2013) - et al.
Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study
Am J Respir Crit Care Med
(2013)
There are more references available in the full text version of this article.
Cited by (0)
Disclosure of potential conflict of interest: I. D. Pavord has consultant arrangements with and has received honoraria from GlaxoSmithKline, AstraZeneca, Novartis, Merck, Boehringer Ingelheim, and Aerocrine and has received travel support from Boehringer Ingelheim and GlaxoSmithKline. M. Bafadhel declares that she has no relevant conflicts of interest.
Copyright © 2013 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.